Recent Quotes (30 days)

You have no recent quotes
chg | %

Aethlon Medical, Inc.  

(Public, NASDAQ:AEMD)   Watch this stock  
Find more results for AEMD
1.04
+0.06 (6.24%)
After Hours: 1.04 0.00 (0.00%)
Nov 20, 6:35PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.01 - 1.09
52 week 0.79 - 5.17
Open 1.03
Vol / Avg. 0.00/463,605.00
Mkt cap 15.70M
P/E     -
Div/yield     -
EPS -0.72
Shares 15.10M
Beta 2.11
Inst. own 17%
Feb 8, 2018
Q3 2018 Aethlon Medical Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 2, 2017
Q2 2018 Aethlon Medical Inc Earnings Call
Nov 2, 2017
Q2 2018 Aethlon Medical Inc Earnings Release
Sep 11, 2017
Aethlon Medical Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin - -1863.63%
Operating margin - -1697.80%
EBITD margin - -1547.16%
Return on average assets -634.23% -343.40%
Return on average equity - -652.83%
Employees 7 -
CDP Score - -

Address

9635 Granite Ridge Dr Ste 100
SAN DIEGO, CA 92123-2678
United States - Map
+1-858-4597800 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.

Officers and directors

James A. Joyce Chairman of the Board, Chief Executive Officer, Secretary
Age: 55
Bio & Compensation  - Reuters
Rodney S. Kenley President, Director
Age: 67
Bio & Compensation  - Reuters
James B. Frakes Chief Financial Officer, Senior Vice President - Finance
Age: 60
Bio & Compensation  - Reuters
Edward G. Broenniman Independent Director
Age: 80
Bio & Compensation  - Reuters
Charles J. Fisher Jr., M.D. Independent Director
Bio & Compensation  - Reuters
Chetan S. Shah M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters